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Summary
Objectives: Lacrimal sac tumors are usually primary and of epithelial origin. Overall, 55% of
lacrimal sac tumors are malignant. Mortality rates for malignant tumors depend on tumor stage
and type, with a mean rate of 38%. The main objective of this study was to review our experience
with these malignancies and to compare this with the published literature.
Patients and methods: A 15-year retrospective review of all malignant lacrimal sac tumor
patients was completed in our department. Seven patients were found to have malignant sac
tumors. The mean age was 53 years (range, 32—74 years) with six women and one man. The
patients’ clinical records were reviewed for data regarding patient symptoms, preoperative
investigations, pathology reports, treatment results, and outcome. These data were compared
with the available literature.
Results: All patients presented with epiphora and a palpable lump of the internal canthus.
In two cases, a history of recurrent dacryocystitis was noted. The histological types were as
follows: squamous cell carcinoma (n = 5), one case of adenoid cystic carcinoma, and one case
of malignant lymphoma. Surgery was performed in six cases with additional radiotherapy in
four. One patient was treated exclusively with external radiotherapy. The mean follow-up was
68months (range, 6—204months). Two patients developed recurrences: three were disease-free
at the time of the study.
Conclusions: Malignant epithelial lacrimal sac tumors are rare cancers with signiﬁcant recur-
rence rates. Correct diagnosis and appropriate therapy require a multidisciplinary management
approach. Treatment of these malignant epithelial tumors is ﬁrst and foremost complete surgical
removal with wide excision.
© 2010 Elsevier Masson SAS. All
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acrimal sac tumors are rare compared to other orbital
umors. Approximately, 400 cases have been reported in
served.
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Figure 1 CT dacryocystography, axial view showing an obsta-
cle to opaciﬁcation of the right nasolacrimal duct.
Figure 2 Malignant tumor of the right lacrimal sac (MRI, axial
view, T1-weighted sequence with contrast agent injection).66
he literature. Early treatment of these tumors is essen-
ial because they tend to be inﬁltrating tumors. Diagnosis
f these tumors is often delayed because they are confused
ith dacryocystitis.
Seven patients with a malignant tumor of the lacrimal
ac were treated between January 1992 and July 2009. The
bjective of this retrospective study was to describe the
ymptoms, preoperative investigations, pathology reports,
herapeutic results, and outcome of these cases and then
ompare them to the data published in the literature. We
ound very few published cases. As such, this study con-
ributes to improving ENT practitioners’ knowledge of these
umors and preventing delayed diagnosis.
atients and methods
even patients with a malignant lacrimal sac tumor were
reated over a period of 17 years (January 1992 to July 2009):
ix females and one male. The patients’ mean age at the
ime of treatment was 53 years (range, 32—74 years).
The seven patients’ clinical records were reviewed
etrospectively for data regarding patient symptoms, pre-
perative investigations, pathology reports, therapeutic
esults, and outcome. Given the small number of cases, no
tatistical analysis of the prognostic factors was performed.
esults
linical symptoms
n all cases, the revealing symptoms were tearing associated
ith a palpable mass in the internal canthus. One patient
resented signs of diplopia due to invasion of the neigh-
oring tissues (case 7). In two cases, an initial erroneous
iagnosis of dacryocystitis had been made (cases 5 and 6).
one of the patients initially complained of pain and none
resented nasal or ophthalmologic bleeding.
ork-up
T dacryocystography was performed for all patients show-
ng a lesion of the internal canthus of the lacrimal sac, with
constant contrast material uptake and no invasion of the
djacent structures (Fig. 1).
Computed tomography (CT) examination of the head and
eck showed opaciﬁcation of the nasolacrimal duct in all
ases, with one case showing an aspect of irregular stenosis
lthough incomplete obstruction (case 3).
Nuclear magnetic resonance imaging (MRI) was per-
ormed in four patients. In all the cases explored with
RI, the tumors showed iso-signal intensity on T1-weighted
mages, with homogenous and moderate gadolinium uptake
Fig. 2). Meningeal involvement was demonstrated in one
atient (case 7).athology report
he ﬁnal pathology ﬁndings demonstrated one case of fol-
icular B-cell non-Hodgkin lymphoma (14%), one case of
pidermoid carcinoma with squamous papilloma (14%), four
Figure 3 Invasive epidermoid carcinoma of the lacrimal sac
(×10).
Malignant lacrimal sac tumors 167
Table 1 Summary of clinical cases.
Patient Sex Age
(years)
Side Histology Initial treatment Complementary
treatments
Progression
1 F 58 Right Squamous
papilloma with
squamous cell
carcinoma zone
Exclusive surgery None 38months
no recurrence
2 F 61 Right Squamous cell
carcinoma
Surgery + parotid + curage + RT Local
recurrence
surgery and RT
118months
no recurrence
3 F 63 Left B-cell
non-Hodgkin
lymphoma
Surgery + immunotherapy Cataract 12months
no recurrence
4 F 51 Right Squamous cell
carcinoma
Surgery and RT Local
recurrence
surgery and RT
Reconstruction
72months
no recurrence
5 F 32 Right Squamous cell
carcinoma
Surgery and RT None 6months
no recurrence
6 F 36 Left Squamous cell
carcinoma
Surgery and RT Reconstruction 204months
no recurrence
7 M 74 Right Cystic adenoid
carcinoma
Exclusive RT None Death at
30months
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mF: female; M: male; RT: radiotherapy; CT: chemotherapy.
cases of invasive epidermoid carcinoma (58%) (Fig. 3), and
one case of adenoid cystic carcinoma (14%).
Therapeutic modalities
The patients were treated differently depending on the local
aggressiveness of the tumor and its histology (Table 1).
The patient presenting cystic adenoid carcinoma did not
undergo surgery because his general health was not good and
it was impossible to completely resect the tumor, given the
massive invasion at the skull base. This patient was treated
exclusively with external radiotherapy at a dose of 62Gy
(case 7).
Case 3 had B-cell non-Hodgkin lymphoma revealed oph-
thalmologically with medullary extension. After surgical
resection, an adjuvant immunotherapy treatment with
rituximab was administered.
Case 1 had areas of micro-invasive squamous cell car-
cinoma that had developed from a squamous papilloma.
Resection via the paralateronasal and endoscopic approach
was considered complete. No complementary treatment was
given.
The four other cases had invasive squamous cell carci-
noma. The tumors were resected via an external approach
(paralateronasal, subciliary, or sublabial) either immedi-
ately (one case) or after biopsy and excision (three cases).
Three cases showed involvement of the adjacent structures,
the nasal bones in one case and orbital fatty tissue in two
cases. Complementary radiotherapy was administered in all
these cases (Fig. 4a,b). No orbital exenteration was per-
formed because of patient refusal and limited invasion of
the orbital fatty tissue (cases 2, 4, 5, 6).
•rogression
he mean follow-up was 68months (range,
—204months).Two patients presented local tumor
ecurrence (cases 2 and 4):
the ﬁrst patient presented suborbital recurrence 5 years
after the ﬁrst intervention. The local recurrence was
treated with surgical resection sacriﬁcing the zygomatic
bone, the orbital ﬂoor, and the anterior wall of the
maxillary sinus followed by new external radiation treat-
ment potentiated at a dose of 50Gy (case 2);
the second patient was followed up for 2 years. Tumor
recurrence was treated surgically and with new local radi-
ation treatment (case◦4).
One patient never achieved remission and the tumor con-
inued to progress (case◦7).
A single patient (case◦2) presented locoregional metas-
ases after the initial surgery: ipsilateral parotid metas-
asis treated with total parotidectomy with ipsilat-
ral functional cervical curage followed by external
adiotherapy.
None of the patients has presented distant metastasis to
ate.
Several complications appeared after therapeutic
anagement:two patients presented healing problems with (1) disunion
resulting in communication of the internal canthus and
the nasal fossae and (2) a tendency toward ectropion of
the lower eyelid. The ﬁrst patient underwent reconstruc-
168
Figure 4 a: postoperative radiotherapy treatment plan
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hdosimetry cross-section at the ethmoid); b: postoperative
adiotherapy treatment plan (dosimetry cross-section at the
axillary sinus).
tion with a glabellar ﬂap and the second with a Mustardé
ﬂap associated with a frontal ﬂap;
one patient experienced osteoradionecrosis of the supe-
rior maxillary with pain requiring a specialized team and
high doses of antalgics;
certain ophthalmological complications occurred,
including two cataracts and one case of keratitis with
corneal ulcerations related to disinsertion of the internal
canthus.
iscussionnalysis of these cases has provided documented data on
even cases of malignant tumors of the lacrimal sac. These
esults compared to the literature contribute to improving
he knowledge on these tumors by describing their clinical,
athological, and progressive characteristics.
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This series includes seven cases diagnosed over a period
f 17 years. Lacrimal sac tumors are rare and their frequency
s poorly known. In an epidemiological study conducted on
705malignant tumors of the eye and its annexes treated
t the Centre hospitalier national d’ophtalmologie des
uinze-Vingts in Paris, only two cases of lacrimal sac tumors
ere counted over a 70-year period [1]. The literature
eports 300—500 cases, most as isolated case studies, with
are series. Six of our seven patients were female, but it is
sually considered that there is no predominance in terms of
thnic origin or gender. In the series reported by Parmar and
ose, 73% of the patients were female [2]. Ni et al. studied
2 patients, with a majority of 57males versus 25 females
3]. Lacrimal sac tumors usually occur in patients around
0 years of age, but they can occur in younger patients [3,4].
The initial diagnosis is often erroneous, with the tumor
istakenly labeled as dacryocystitis [5]. These patients are
ften referred later after discovery of a malignant tumor
n biopsies of the lacrimal sac taken when dacryocystitis
ecurs. Two of the cases studied herein had been diagnosed
ith dacryocystitis. The duration of symptom progression
efore diagnosis varies. For some, fewer than 15% of patients
re diagnosed within 2months. On the other hand, for 72%
f the patients, treatment begins within 1 year [3].
The most frequent symptom is tearing. Tumefaction of
he internal canthus is often found. All of our patients associ-
ted tearing with an internal canthus mass. The presence of
hard tumefaction located above the medial canthal tendon
s highly suspicious of being a malignant lacrimal sac tumor.
he signs are nearly always unilateral. Endoscopic examina-
ion of the nasal fossae searches for invasion and continuity
f the nasal fossa and the sinusal cavities and explores the
nferior meatus to identify any tumor process arising in the
asolacrimal duct. When the tumor is visible on the endo-
copic exam, endonasal biopsy should be performed, which
an be done in consultation. At the beginning of tumor pro-
ression, instrumental exploration of the lacrimal ducts may
eturn normal results with ﬂuid passage preserved during
avage and good bone contact during probing. Later, the
acrimal duct becomes impermeable. Normal instrumental
xploration, therefore, does not eliminate the possibility of
alignant tumor of the lacrimal sac.
The radiological work-up should include CT dacryocys-
ography with and without injection of contrast material,
ith axial and coronal views, as well as T1- and T2-weighted
RI sequences with gadolinium injection. Dacryocystog-
aphy can demonstrate a defect during opaciﬁcation
f the lacrimal sac: it is increasingly replaced by CT
acryocystography.
CT dacryocystography demonstrates more or less limited
pacity of the internal canthus with, in a certain number of
ases, associated osteolysis. Opaciﬁcation of the lacrimal
ucts shows an obstacle as the contrast agent passes
hrough. We found this aspect in all of our cases. MRI shows
n intermediate-signal lesion on T1-weighted sequences
nd a hypo-intense signal on T2-weighted images. This
ypo-intense signal on T2-weighted sequences should be a
arning sign because inﬂammatory dacryocystitis presents
hyperintense signal on T2-weighted images [6]. This lesion
akes up the contrast agent moderately after gadolinium
njection, sometimes heterogenously. This imaging tech-
ique stages the tumor locally given that it differentiates
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Table 2 Histology of malignant tumors of the lacrimal sac.
Histology Parmar and Rose,
2003
Sagerman et al.,
1994
Pe’er 1994 Ni et al.,
1982
Flanagan and
Stokes, 1978
Malignant epithelial tumors Squamous cell carcinoma 2 22 Not evaluated 9 76
Transitional carcinoma 2 5 6
Squamous cell and
transitional
carcinoma
1 0 0
Adenocarcinoma 0 2 3
Oncocytic adenocarcinoma 0 2 0
Mucoepidermoid carcinoma 1 3 4
Undifferentiated carcinoma 1 1 18
Cystic adenoid carcinoma 1 3 0
Carcinomas with papilloma 0 6 31
Non-epithelial malignant tumors Malignant lymphoma 5 8 8 0 52 (including
8melanomas)
Melanoma 0 6 8 0
Sarcoma 0 1 1 1
Malignant granuloma 0 0 0 2
Total 13 59 17 74 128
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he tumor from retained secretions and evaluates invasion
f the adjacent structures as orbital fatty tissue, the ocu-
omotor muscles, the periorbit, and the meninges. It is also
aluable in postoperative follow-up.
Different clinical and radiological markers can differen-
iate an inﬂammatory lesion from a tumoral lesion. The
resence of tumefaction above the medial canthal tendon,
peed of progression, invasion of neighboring anatomical
tructures, and resistance to usual treatments are indica-
ions that a tumor may be present. From a radiological point
f view, the lytic aspect on CT argues in favor of a malig-
ant pathology, whereas a spontaneous hyperintense signal
n MRI in T2-weighted sequences suggests an inﬂammatory
r infectious etiology.
The pathological diagnosis can be made on biopsy [7].
hen the tumor is visible on the endonasal exam, the biopsy
an be done under the microscope in consultation after local
nesthesia. With a high clinical and/or radiological suspicion
f malignity, the biopsy should be analyzed extemporane-
usly and surgical resection completed in a patient who
as been informed of this possibility beforehand. Classi-
ally, the biopsy is performed via a direct approach at the
nternal canthus. This approach presents the advantage of
ossible enlarging via a transfacial approach. The role of
ndoscopic biopsy has not been clearly deﬁned to date. In
certain number of cases, a malignant tumor is diagnosed
uring the histological analysis of a lacrimal sac biopsy done
t the time of a dacryocystorhinostomy. However, biopsy
hould be systematic when the clinical history or exami-
ation raises the suspicion of a possible tumoral origin or
he intraoperative aspect is unexpected [8]. The utility of
ytopuncture of the lacrimal sac in the etiological work-up
f a lacrimal sac tumefaction also remains poorly deﬁned.
ytopuncture could become a simple means to orient the
iagnosis and inform the patient without risking tumoral
pread. This cytopuncture technique requires further assess-
ent.
Lacrimal sac tumors are malignant in 55% of cases [4],
ith a distinction made between epithelial tumors and non-
pithelial tumors. Epithelial tumors account for more than
wo-thirds of all the malignant tumors of the lacrimal sac
2,4]. In the epithelial tumor category, epidermoid carcino-
as are the most frequent malignant tumors, in agreement
ith the 58% rate of invasive squamous cell carcinoma found
n our series. These tumors can occur by degeneration of
n endophytic papilloma (one case in our series). As for
ther locations, certain authors have taken an interest in
he involvement of human Papillomavirus (HPV) in the onset
f epithelial tumors of the lacrimal sac. The role played
y HPV-16 and -18 in the onset of malignant or dysplastic
esions of the lacrimal sac is discussed by certain authors [9].
he other malignant epithelial tumors are transitional car-
inomas, mucoepidermoid tumors, adenocarcinomas, and
ystic adenoid carcinomas. Transitional squamous cell carci-
oma is invasive and locally recurrent [10]. Mucoepidermoid
arcinoma may originate in the serous glands belonging to
he epithelium of the walls of the lacrimal sac [11]. A few
ases of adenocarcinoma have been described. An adeno-
arcinoma can occur de novo or by transformation of a
leomorphic adenoma after several years of epiphora [12].
hese glandular tumors could originate in the mixed or
erous glands present within the lacrimal ducts [13].
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In the category of non-epithelial tumors, which account
or less than one-third of the malignant tumors of
he lacrimal sac [14,15], essentially mesenchymatous
umors, lymphoid tumors, sarcomas, and often aggressive
elanomas are found. Lymphomas account for approxi-
ately 6% of lacrimal sac tumors. Malignant lymphomas are
or the most part B-cell non-Hodgkin lymphomas, as in our
eries. They are most frequently secondary to a generalized
ymphoma, but cases of primary tumors of the lacrimal
ac have been described [16]. Mucosa-associated lymphoid
issue (MALT) lymphomas can occur in the lacrimal sac, con-
idered a low-grade lymphoma when it is a B phenotype
17]. In 2006, Sjö et al. described 15 cases of primary
ymphoma of the lacrimal sac, 33% of which were MALT
ymphoma [18]. Melanomas are very rare, with approxi-
ately 20 cases reported in the literature. The onset of
elanoma of the lacrimal sac is difﬁcult to explain because
here are no melanocytes in the normal drainage tear ducts.
hese melanocytes could be of ectopic origin through an
nomaly during migration of neural crest cells. The histolog-
cal diagnosis of melanoma can be difﬁcult. Histochemical
nformation can be useful because melanoma is reactive
uring immunostaining of S-100 protein and HMB-45 [19].
The distribution of malignant tumors in different series
ccording to their histology is illustrated in Table 2. The
istological classiﬁcations have evolved, notably based on
mmunohistochemistry, which has made it possible to better
pecify tumors that are difﬁcult to diagnose. It is probable
hat some tumors belonging to the oldest series would have
een classiﬁed differently today.
Treatment of malignant tumors of the lacrimal sac
epends for the most part on the histological type, the
umor extension, and the patient’s general health. Either
he diagnosis of tumor is deﬁned preoperatively or it is dis-
overed intraoperatively. In all cases, it is recommended
o extemporaneously analyze the tumor biopsy. Biopsies
hould be deep because chronic inﬂammation develops in
he tumor periphery and can result in erroneous diagno-
is of inﬂammatory pseudotumor. If the diagnosis cannot
e made during extemporaneous examination, it is advised
ot to perform osteotomy before the ﬁnal histological result
ecause of the risk of tumor contamination if surgical resec-
ion is not complete. When necessary, wide resection is the
hoice treatment of most malignant lacrimal sac tumors
20]. Complete resection of the lacrimal drainage ducts
s recommended, sacriﬁcing the superior and inferior tear
ucts, the lacrimal sac, the nasolacrimal duct, the lacrimal
ossa, and the adjacent lacrimal ethmoid cells. A combined
xternal-endonasal approach can be useful to remove the
ntire lacrimal apparatus to the inferior meatus [20]. The
ransfacial approach is the most frequently chosen. In cases
f large inﬁltrating tumors, orbital exenteration may be
ecessary. In our team, invasion of the orbital fatty tissue
s not an absolute indication for ﬁrst-line orbital exentera-
ion if tumor extension remains limited. The gain provided
y orbital exenteration in terms of local control and long-
erm survival is difﬁcult to assess when orbital invasion is
imited because of the low number of cases reported in
he literature. Disﬁgurement related to surgery is, however,
ajor. Orbital exenteration is justiﬁed in cases of major
nvasion of the orbital cone or of tumor recurrence after
djuvant radiotherapy.
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Radiotherapy can be the exclusive treatment when the
tumor is deep-rooted or when surgery is refused by the
patient or is contra-indicated [21]. The immediate toxicity
of radiotherapy is low and is limited to conjunctival or cuta-
neous hyperemia. One of the risks of radiation is reduction in
visual acuity, which can occur with doses of 50Gy delivered
on the optic nerve or the retina. Delayed toxicity leads to
xerophthalmia, radiation retinopathy, glaucoma, cataract,
or keratitis with corneal ulcerations [21,22,23]. A protective
shell can be used to limit these risks.
Surgical treatment associated with radiotherapy can
result in disﬁgurement requiring reconstructive surgery.
Surgical resection of the nasal bones associated with
postoperative radiation of the tumor site can result in later
canthal necrosis. The esthetic damage is major and requires
repair solutions. However, this esthetic damage should not
be an obstacle to tumor resection, which should also be
as wide as possible. Cutaneous resection can sometimes be
imperative. Reconstruction surgery should be planned for
after radiotherapy when the disease has been demonstrated
not to be progressing. The surgical project can prefer local
reliable ﬂaps such as a nasofrontal ﬂap or a Mustardé ﬂap if
substance loss remains limited. In cases of a more extensive
defect, notably at the nasal pyramid or the orbit, the use of
free ﬂaps may be necessary. In weak patients, the solution
of epithesis is always possible.
Recurrences most often occur locally and can be revealed
late. In the present series, one of the two local recurrences
of epidermoid carcinoma occurred 5 years after initial treat-
ment. For Ni et al., the recurrence rate is directly related to
initial tumor excision, with 12.5% recurrence for wide exci-
sion versus 43.7% recurrence in cases of isolated lacrimal
sac resection [3]. They also showed that when exentera-
tion is required, the prognosis remains poor, with mortality
reaching 50% even in cases of radical surgery with tumor
excision via the transfacial approach associated with orbit
exenteration followed by radiation treatment [3]. In a series
of malignant tumors of the lacrimal sac treated at the Rouen
University Hospital, a case of cystic adenoid carcinoma
recurred locally and metastasized 13 years after the initial
diagnosis [24]. Recurrences are frequent, with a 50% rate
for carcinomatous lesions and in 50% of cases recurrence is
fatal. Local recurrences are treated on a case-by-case basis
with surgery and/or radiotherapy.
Metastatic adenopathies are rarer than local recur-
rences; they are preferentially parotidean, submaxillary, or
jugulocarotid. In our series, one case of parotid metasta-
sis of a squamous cell carcinoma was found. In the series
reported by Parmar and Rose, a single patient developed
metastatic cervical adenopathies; he was a carrier of B-cell
non-Hodgkin lymphoma [2].
Metastases are rare and most frequently pulmonary. In
the series reported by Ni et al. comprising 74malignant
tumors, 28% of the patients presented lymph node invasion
and six presented metastases (four to the lungs and two to
the esophagus) [3]. In a series of 15 lacrimal sac tumors, Par-
mar and Rose found two cases of patients who died of rapid
metastatic progression. Another of the patients is still alive
but has lung metastases requiring radiotherapy [2].
In the series described by Stefanyszyn et al., six patients
out of 115 died: three of local recurrences, one of metas-
tasis to the lungs, and two of surgical complications after
[
[171
umor resection [4]. One of our patients died of local tumor
rogression of a cystic adenoid carcinoma that invaded the
nterior skull base and the dura mater.
onclusion
n conclusion, it should be remembered that malignant
umors of the lacrimal sac are rare and often initially diag-
osed as dacryocystitis. These tumors carry a vital risk and
hould be immediately managed with maximum care. Treat-
ent should be decided within a multidisciplinary team and
lose, long-term monitoring is indispensable.
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